Recent

% | $
Quotes you view appear here for quick access.

Insmed Incorporated Message Board

  • califflaa califflaa Apr 7, 2014 3:12 AM Flag

    Prophylaxis and Treatment of NTM Disease ATS-IDSA standard of care for NTM

    From the American Thoracic Society website:

    Prophylaxis and Treatment of NTM Disease
    1. Treatment of MAC pulmonary disease. For most patients with nodular/bronchiectatic disease, a three-times-weekly regimen of clarithromycin (1,000 mg) or azithromycin (500 mg), rifampin (600 mg), and ethambutol (25 mg/kg) is recommended. For patients with fibrocavitary MAC lung disease or severe nodular/bronchiectatic disease, a daily regimen of clarithromycin (500โ€“1,000 mg) or azithromycin (250 mg), rifampin (600 mg) or rifabutin (150โ€“300 mg), and ethambutol (15 mg/kg) with consideration of threetimes-weekly amikacin or streptomycin early in therapy is recommended. Patients should be treated until culture negative on therapy for 1 year.
    2. Treatment of disseminated MAC disease. Therapy should include clarithromycin (1,000 mg/d) or azithromycin (250 mg/d) and ethambutol (15 mg/kg/d) with or without rifabutin (150โ€“350 mg/d). Therapy can be discontinued with resolution of symptoms and reconstitution of cellmediated immune function.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
INSM
12.50-0.31(-2.42%)1:43 PMEST